Neuren Pharmaceuticals Updates on Share Buy-Back Progress

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an announcement.

Neuren Pharmaceuticals Limited announced an update on its ongoing share buy-back program, reporting the buy-back of 13,421 ordinary fully paid securities on the previous day, bringing the total to 3,635,139 securities bought back. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its equity base.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work on treatments for conditions such as Rett syndrome and Fragile X syndrome, aiming to address significant unmet medical needs in these areas.

Average Trading Volume: 761,156

Technical Sentiment Signal: Buy

Current Market Cap: A$1.79B

For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.